IL1B and heart disorder: Clinical treatment of atherosclerotic cardiovascular disease for intrinsic immunity is relatively mature, as evidenced in the Shen’s study to reduce cardiovascular recurrence events by using IL-1β antibodies in patients with a history of heart disease who still have inflammatory residues after standard treatment [21].